Showing posts with label aging. Show all posts
Showing posts with label aging. Show all posts

Monday, February 26, 2007

Loneliness Increases Risk for ALzheimer's Disease-Like Dementia

"Social isolation in old age has been associated with risk of developing dementia, but the risk associated with perceived isolation, or loneliness, is not well understood," write Robert S. Wilson, PhD, of the Rush University Medical Center in Chicago, Illinois, and colleagues. "We examined these issues using data from the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic conditions of old age."



Source Medscape

Lonely elderly patients are more than twice as likely to develop Alzheimer's disease (AD)-like dementia than those who are not lonely, according to the results of a 4-year cohort study reported in the February issue of the Archives of General Psychiatry. However, pathology did not reveal Alzheimer's disease or cerebral infarction, suggesting that novel mechanisms may be involved.

"Social isolation in old age has been associated with risk of developing dementia, but the risk associated with perceived isolation, or loneliness, is not well understood," write Robert S. Wilson, PhD, of the Rush University Medical Center in Chicago, Illinois, and colleagues. "We examined these issues using data from the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic conditions of old age."

At baseline and annually thereafter for up to 4 years, 823 participants recruited from senior citizen facilities in and around Chicago, underwent uniform in-home evaluations including detailed cognitive function testing, clinical classification of dementia and AD, and assessment of loneliness with a modified version of the de Jong-Gierveld Loneliness Scale. For participants who died, uniform postmortem evaluation of the brain quantified AD pathologic abnormalities and cerebral infarction.

On the 5-item loneliness scale, mean baseline score was 2.3 ± 0.6. During follow-up, 76 subjects developed clinical AD, based on previously established composite measures of global cognition and specific cognitive functions.

Compared with persons who were not lonely (score, 1.4; 10th percentile), risk for AD was more than doubled in lonely persons (score, 3.2; 90th percentile). Controlling for indicators of social isolation did not affect this finding. Loneliness was associated with lower level of cognition at baseline and with more rapid cognitive decline during follow-up. There was no significant change in loneliness during the study, and mean degree of loneliness was robustly associated with cognitive decline and with development of clinical AD.

In 90 participants who died and had brain autopsy, loneliness was unrelated to summary measures of AD pathology or to cerebral infarction.

"Loneliness is associated with an increased risk of late-life dementia but not with its leading causes," the authors write.

Study limitations include predominantly white volunteer cohort, mean observation period less than 3 years, only 76 cases of incident AD, and only 90 autopsies performed.

"The perception of being alone was associated with cognitive decline and development of an AD-like dementia even after controlling for objective indexes of social isolation and other covariates," the authors conclude. "Neither AD pathology nor cerebral infarction could account for the association, suggesting that novel neurobiologic mechanisms may be involved."

The National Institute on Aging and the Illinois Department of Public Health supported this study. The authors have disclosed no relevant financial relationships.

Arch Gen Psychiatry. 2007;64:234-240.

Clinical Context

Little is known about the association of dementia and emotional isolation, although social isolation, defined as having a small social network, being unmarried, and participating in few activities with others, has been associated with increased risk for dementia.

This is a prospective cohort study within the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic diseases of old age. Loneliness was assessed using a modified version of the de Jong-Gierveld Loneliness Scale, and patients were followed up for incidence of AD and cognitive impairment, and brain autopsies were performed at death.

Study Highlights

Inclusion criteria were absence of dementia and living in retirement communities, subsidized housing, local churches, or social services agencies.
At baseline, all participants underwent structured history, cognitive testing, and comprehensive assessment for AD.
The criteria for AD were from the joint working group of the National Institute of Neurological and Communicative Disease Disorders and Stroke-Alzheimer Disease and Related Disorders Association.
A modified version of the de Jong-Gierveld Loneliness Scale with a 5-point Likert scale was used for self-reported symptoms of loneliness.
Social isolation was assessed by social network size and frequency of participation in social activity, rated on a 5-point scale.
Depressive symptoms were assessed with a 10-item form by the Center for Epidemiological Studies–Depression scale for 9 cognitive activities.
Physical functioning was assessed using the Health Interview Survey.
At each annual evaluation thereafter, 20 cognitive tests were administered including the Mini-Mental State Examination and 19 tests with 7 measures of episodic memory.
A composite measure based on all 19 test results was used to quantify cognitive decline.
Postmortem brain autopsy was performed in subjects who died.
857 subjects completed at least one follow-up evaluation.
Mean follow-up period was 3 years.
Mean age was 81 years, 76% were women, mean years of education was 14 years, 91% were white, 66% lived in retirement homes, 30% in single family homes, and 4% in assisted-living settings.
Loneliness was negatively correlated to social network size, frequency of social activity, and cognitive activity and education.
76 subjects developed dementia that met AD criteria.
Those who developed AD were older, more likely to be men, had lower cognitive function, lower income, and higher levels of loneliness and disability.
The risk for AD increased by 51% for each point on the loneliness scale (relative risk [RR], 1.51).
A person with a high degree of loneliness (90th percentile for score) was 2.1 times more likely to develop clinical AD compared with someone with a low degree of loneliness (10th percentile for score).
More frequent social activity was associated with reduced AD risk (RR, 0.52).
Loneliness was inversely related to level of cognitive activity.
The association of loneliness with AD was unchanged after adjustment for race, income, disability, and vascular risk factors.
Loneliness was inversely related to baseline level of function on each cognitive measure.
Loneliness was associated with more rapid decline in global cognition, semantic memory, perceptual speed, and visuospatial ability.
There was no significant change in loneliness during the study.
135 subjects died, and brain autopsy was performed on 90 subjects.
Baseline loneliness score was unrelated to a global measure of AD pathology identified by silver stain, percentage area occupied by amyloid plaques, and density of neurofibrillary tangles.
The authors concluded that the association between loneliness and AD or cognitive decline was not mediated by AD pathology or cerebral infarction.

Pearls for Practice

In elderly persons, those with loneliness vs those without loneliness have an increased risk for AD-like dementia.
Loneliness is not related to AD pathologic findings or cerebral infarction.






Wednesday, February 07, 2007

Loneliness and Alzheimer's Linked

"People who are lonely are twice as likely to develop Alzheimer's disease, a large US study has suggested."

Read this article at The Senior Reading Room

Sunday, February 04, 2007

Huperzine A in Alzheimer's Disease-The Clinical Trial

"The Huperzine A in Alzheimer's Disease clinical trial is currently open and recruiting patients. This is a Phase II clinical trial."

Read about the study including requirements and available locations at The Alzheimer's Reading Room: Huperzine A in Alzheimer's Disease-The Clinical Trial.

Monday, January 15, 2007

New Gene Linked to Alzheimer's

"It fits into what we believe is the main mechanism of Alzheimer's already," Gandy said. "This reinforces the idea that we're on the right track with therapies already in the pipeline, while also suggesting a totally new strategy that could be used to target entirely new classes of drugs."

To read the article in its entirety go to the The Alzheimer's Reading Room.

Friday, January 05, 2007

Decoding Alzheimer's: After a century, promising treatments at last—and whispers of a cure

This is a fascinating article that discusses treatments for Alzheimer’s disease that are on the near term horizon.

"After a century, promising treatments at last—and whispers of a cure"

Read this article in its entirety at The Alzheimer’s Reading Room

Thursday, December 28, 2006

Keeping Time with Alzheimer"s

This is an excellent article that can be read in its entirety at the Alzheimer's Reading Room.


"When guilt catches up with me, I am on the bike path above the creek, ducks swimming along beside me. Guilt rolls off our backs like you know what. Alone at last, I walk at my own pace. Fast. Fast is what Ben can no longer do -- and fast is slow compared with the woman coming toward me as I near the marsh. She is wearing shorts and earphones. She smiles and I smile back. What a good idea this is, walking out in the sun and cold. What could produce better clarity? I don't have to work it out the first day. I don't have to do it right the first time."










Tuesday, November 21, 2006

The CareGiver: Benefits Check Up for Seniors

I recently stumbled on to BenefitsCheckUp offered by the National Council on Aging. All you need to do is fill out a short questionairre and the program identifies private and/or government programs that help pay for prescription drugs, health care, utilities, and other needs of seniors. Once you complete the questionairre the computer instantly generates a list of agencies and contact information that fit your profile. I was able to identify a real estate exemption that will save my mother more than $330 annually.





The questionairre is easy to understand and to fill out. It generates the results instantly. Since it check across all kinds of federal, state and local agencies it saves you the time of calling each one or filling out seperate questionairres. In terms of time it will save you many hours and it also provides contact information that was of great value to me.

This program makes it very easy to determine if you are eligible for additional Medicare or Medicaid benefits. It also determines if their are state or local tax exemptions or help with bills such as electricity.

Here is the link to BenefitsCheckUp

If you find this of value please pass on the link or feel free to send others to this blog.

Bobby

The CareGiver Blog


Robert T DeMarco


AllAmerican Senior Care


AllAmerican Senior Care Weblog





Saturday, November 18, 2006

The CareGiver: Huperzine A Factsheet (Alzheimer's)

I recently read about Huperzine A. The following page contains a fact sheet about the herb. Huperzine A may have cognition-enhancing activity in some.






Source Huperzine A


TRADE NAMES

Huperzine A is available from numerous manufacturers generically. Branded products include Memorall (PharmAssure), Huperzine Rx-Brain (Nature's Plus).

DESCRIPTION

Huperzine A is a plant alkaloid derived from the Chinese club moss plant, Huperzia serrata, which is a member of the Lycopodium species. Huperzia serrata has been used in Chinese folk medicine for the treatment of fevers and inflammation.

Huperzine A has been found to have acetylcholinesterase activity. Huperzine B, also derived from Huperzia serrata, is a much less potent acetylcholinesterase inhibitor. Natural huperzine A is a chiral molecule also called L-huperzine A or (-)-huperzine A. Synthetic huperzine A is a racemic mixture called (±)-huperzine A. Huperzine A is also known as HUP, hup A and selagine. In Chinese medicine, the extract of Huperzia serrata is known as Chien Tseng Ta and shuangyiping. Huperzine A derivatives are being developed for pharmaceutical application.

ACTIONS AND PHARMACOLOGY ACTIONS

Huperzine A may have cognition-enhancing activity in some.

MECHANISM OF ACTION

Alzheimer's disease is a neurodegenerative disorder associated with neuritic plaques that affect the cerebral cortex, amygdala and hippocampus. There is also neurotransmission damage in the brain. One of the major functional deficits in Alzheimer's disease is a hypofunction of cholinergic neurons. This leads to the cholinergic hypothesis of Alzheimer's disease and the rationale for strategies to increase acetylcholine in the brains of Alzheimer's disease patients. Two FDA-approved drugs for the treatment of Alzheimer's disease, tacrine and donepezil, are acetylcholinesterase inhibitors.

Huperzine A is also an acetylcholinesterase inhibitor and has been found to increase acetylcholine levels in the rat brain following its administration. It also increases norepinephrine and dopamine, but not serotonin levels. The natural L or (-)-huperzine A is approximately three times more potent than the racemic or (±)-huperzine A in vitro.

PHARMACOKINETICS

There are limited pharmacokinetic studies with huperzine A. It appears that huperzine A is rapidly absorbed from the gastrointestinal tract and transported to the liver via the portal circulation. Some first-pass metabolism takes place in the liver, and huperzine A and its metabolites are distributed widely in the body, including to the brain. Following ingestion, the time to reach peak blood level is approximately 80 minutes.

INDICATIONS AND USAGE

Huperzine A has potent pharmacological effects and, particularly since long-term safety has not been determined, it should only be used with medical supervision. It may have some effectiveness in Alzheimer's disease and age-related memory impairment. It has been used to treat fever and some inflammatory disorders, but there is no credible scientific evidence to support these uses.

RESEARCH SUMMARY

Numerous studies, most of them from China, suggest that huperzine A may be as effective as the drugs tacrine and donepezil in Alzheimer's disease. This is not so surprising since in vitro and animal model tests have demonstrated that huperzine A effectively inhibits acetylcholinesterase, an enzyme that catalyzes acetylcholine breakdown. Tacrine and donepezil work in the same way to conserve acetylcholine in the brain--the mode by which they presumptively improve memory and cognition in those with Alzheimer's and age-related cognitive impairment. Huperzine A may prove superior to tacrine (dose-limited due to its hepatotoxicity) if long-range studies, yet to be conducted, demonstrate its safety.

In one double-blind, randomized study, huperzine A, in injectable form, was tested against a saline control in 56 patients with multi-infarct dementia or senile dementia and in 104 patients with senile and pre-senile simple memory disorders. Huperzine A produced significant positive effects as measured by the Wechsler Memory Scale. Dizziness was experienced by a few of the huperzine A-treated patients.

In another study, this one multicenter, double-blind, placebo-controlled and randomized, 50 subjects with Alzheimer's disease were given huperzine A or placebo for eight weeks. Significant improvement was noted in 58 percent of the patients in terms of memory, cognitive and behavioral functions. Research is ongoing.

CONTRAINDICATIONS, PRECAUTIONS, ADVERSE REACTIONS CONTRAINDICATIONS

None known.

PRECAUTIONS

Huperzine A should be avoided by children, pregnant women and nursing mothers.

Because of possible adverse effects in those with seizure disorders, cardiac arrhythmias and asthma, those with these disorders should avoid huperzine A. Those with irritable bowel disease, inflammatory bowel disease and malabsorption syndromes should avoid huperzine A.

ADVERSE REACTIONS

Adverse effects reported with huperzine A include gastrointestinal effects, such as nausea and diarrhea, sweating, blurred vision, fasciculations and dizziness. Possible adverse effects include vomiting, cramping, bronchospasm, bradycardia, arrhythmias, seizures, urinary incontinence, increased urination and hypersalivation.

INTERACTIONS DRUGS

Acetylcholinesterase Inhibitors: Use of huperzine A along with the acetylcholinesterase inhibitors donepezil or tacrine may produce additive effects, including additive adverse effects. Other acetylcholinesterase inhibitors include neostigmine, physostigmine and pyridostigmine, and use of these agents along with huperzine A may produce additive effects, including additive adverse effects.

Cholinergic Drugs: Use of huperzine A along with cholinergic drugs, such as bethanechol, may produce additive effects, including additive adverse effects.

NUTRITIONAL SUPPLEMENTS

Use of huperzine A with choline, phosphatidylcholine, CDP-choline and L-alpha-glycerylphosphorylcholine hypothetically might produce additive effects, including additive adverse effects.

OVERDOSAGE

There are no reports of overdosage with huperzine A.

DOSAGE AND ADMINISTRATION

There are various forms of huperzine A available, including extracts of Huperzia serrata, natural (-)-huperzine A and synthetic racemic (±)-huperzine A. Natural (-)-huperzine A is approximately three times more potent than the synthetic racemic mixture. The doses of natural (-)-huperzine A used in clinical studies ranged from 60 micrograms to 200 micrograms daily. Huperzine A should only be used with a physician's recommendation and monitoring.

HOW SUPPLIED

Capsules — 50 mcg

Tablets — 50 mcg

LITERATURE

Cheng DH, Tang XC. Comparative studies of huperzine A, E-2020 and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav. 1998; 60:377-386.

Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996; 8:97-101.

Quian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Chung Kuo Yao Li Hsueh Pao. 1995; 16:396-398.

Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol. 1994; 44:147-155.

Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav. 1995; 51:415-419.

Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Chung Kuo Yao Li Hsueh Pao. 1995; 16:391-395.

Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther. 1999; 288:814-819.

Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. [Article in Chinese] Chung Kuo Yao Li Hsueh Pao. 1991; 12:250-252.










Friday, November 17, 2006

Huperzine A in Alzheimer's Disease

I just finished reading an interesting article about Huperzine A. You can get an excerpt, the link to the article and the link to the clinical trial on the next page.




Follow this link to get the information about the clinical trial, Huperzine A in Alzheimer's Disease


Alzheimer's herb

Here is an excerpt from the article:

Karen says when it comes to her mom, "It made her want to get up out of the chair, it made her want to go out to the pool and swim laps, it made her want to go out and prune her flowers."

Another benefit Betty's family has seen: she has lost 50 pounds because she has been more active. Dr. DeCarli said this is just one example of clinical trials in action.

Follow this link to the complete article, Herb


All American Senior Care

The CareGiver





Wednesday, November 15, 2006

The Silver Tsunami

The Baby Boomers are coming...What looms for this generation?







By Andra Coberly

With a thriving post-World War II economy and soldiers returned from service, the men and women of America did their civic duty.

And they did it again and again and again.

The Baby Boom began 60 years ago when economic prosperity—as it often does—translated into a flood of offspring. By the end of the 1940s, close to 32 million babies had been born, and families of 10 were not uncommon. The “fruit of demobilization,” a term coined by the Washington Post, didn’t end until 1964. Boomer Nation was about 75 million strong—a diverse generation defined by the Vietnam War, sexual revolution and even disco.

What concerns some is that the boom of babies between 1946 and 1964 will become a tsunami of seniors in 15 to 20 years. While Boomers will be the first to tell you how active, healthy and stable they are, the aging of this generation is now considered a looming crisis.

Ten million Americans will be 85 years or older by 2030, and Larimer County’s 75 and older population is expected to surge 48 percent between 2005 and 2020. With a large number of older seniors, some expect serious strains on the programs they often rely upon.

Actually, “strain” is an understatement when describing how these masses will impact the system in 20 years—a system that includes everything from social security to dental care to congregate meals to Medicare.

“Detriment” might be more appropriate.

When one turns 75, the likelihood of being placed in a nursing home or long-term care facility increases greatly. Aging, often, leads to more medical oversight, more medication and more services from federal, state or local entities.

According to Margaret Long of the Larimer County Office on Aging, funding is currently not meeting the needs of the community’s elderly. And when Larimer County’s 75 and older population hits 19,000 in 2020—as it’s expected to do—funding will increasingly fail to help those in need.

“We must keep providing service and we must also plan for the demographics and change in numbers,” Long says. “This is the time we have to start setting the wheels in motion.”

If agencies like Department of Human Services do not plan for this senior tsunami, as Long calls it, they will not be prepared to handle the need. While it is clear that the impacts of the aging Boomer population may not be known for at least 15 to 30 years, Long and others are beginning to prepare so this tsunami doesn’t turn into a disaster.

“It’s going to be a challenge to us all,” says Jill Taylor, manager of Poudre Valley Health System’s Aspen Club, which provides educational and screenings to local seniors. “But it’s a good challenge.”

Issues beyond funding are also expected to arise. Physicians and mental health practitioners who specialize in geriatric care will be in high demand. Senior-care businesses will likely be overrun with clients. And health-care facilities will be forced to change their offerings for a generation that is not afraid to demand its morning lattés and private rooms.

Largely, Baby Boomers will push the definition of what it means to be old. In fact, their maturity has been, and will continue to be, the focus of a certain amount of speculation.

“I don’t know what it will look like but I know the Boomers are not looking like status quo,” says Yvonne Myers, health systems coordinator for Columbine Health Systems.

Gary Sheldon couldn’t agree more that there is no way to pigeonhole the Baby Boomer generation.

“We’re a diverse group,” he says.

But as the 52-year-old talks about himself and his future, he realizes that he is a specimen of his generation.

“I’m the quintessential Baby Boomer, aren’t I?” he says, interrupting himself.

Sheldon is active, an enthusiastic cyclist, and he plans to stay spry and healthy into his older years. He hopes to see his grandchildren grow up, and the orthodontist feels comfortable about his plans for retirement and his aging—though he resists the term “senior.”

“It implies sedentary,” he says.

Sheldon seems to have his future set, like many his age who plan to spend their senior years traveling, doing yoga and taking bike tours of Italy.

But a large percentage of Sheldon’s generation will not be so lucky.

While several studies show the health and quality of life of older adults is steadily increasing, some worry that the growing senior population will translate into sizable numbers living in poverty, without health insurance and alone—requiring health care, nutrition, transportation and others services from government entities.

In a study by The Population Reference Bureau, two sociologists say Baby Boomers will stay employed and active longer. But, they counter, the group is also characterized by huge economic inequalities and a large population without health insurance—many Baby Boomers will be less healthy and less wealthy than seniors before them. Younger Boomers, now in midlife, have the highest poverty levels since before to World War I. Plus, there will be fewer workers contributing to endowments like Medicare and Social Security than there are now.

For Larimer County, that means that Department of Human Services and some non-profits will increasingly struggle to provide. The Office on Aging, a division of Department of Human Services, offers multiple services for the county’s elderly. Long, the program’s director, recently presented its four-year plan, the office’s predicted spending between 2007 and 2011. Simply, the budget holes over the next four years are gaping. The estimated funding shortfall for just the office’s external services could pass $200,000 by 2011.

Long considers her work on the four-year plan the start of preparation for the gigantic wave of feisty, silver-haired seniors.

“The really critical thing when looking at the Baby Boomers is to use the next eight years for planning,” she says.

The potential for a flood of seniors drives several issues for Long and others.

One is the need for more doctors and mental health specialists. Doctors will need to be aware of how medications and treatments affect aging bodies. Mental disorders such as depression and bipolar are increasingly problematic, and according to Long, “There are some real shortages in terms of practitioners who really specialize in the mental health issues of the geriatric population.”

No matter the specialty, Myers says, “if you are in the health-care business, you’ll want to like taking care of old people.”

The Baby Boomers, living longer and healthier, will post new challenges for those doctors. Finding and funding dental care—a new problem since seniors in the past largely didn’t have their teeth and required dentures—is a concern. As is learning to better treat those in their 100s, as that demographic is likely to grow.

Those who run nursing-care and assisted-living facilities expect Baby Boomers to remodel their services. Nursing-home activity directors, Myers says, will have one hell of a time pleasing the musical tastes of this generation—from The Beatles to John Fogerty to Michael Jackson. Nutrition programs, like congregate meals and fixed menus, will also need to be rethought.

“There was a woman in her 50s in here the other day and she said she would starve to death if she lived here,” Myers says. “She said she was a vegetarian, she’ll need her soy milk and tofu. I thought, ‘I’m not moving any place unless there’s an espresso machine.’”

Not all of this anticipation is treated like preparation for Armageddon.

Myers hopes the attention will bring a new appreciation for the elderly.

“It’s awesome when you’re a senior in high school,” says Myers, a Baby Boomer herself. “But not so much when you’re a senior in life. My hope is that we come to value their wisdom and value the roles that older people play.

“It’s an exciting time to be a senior,” she continues. “It’s a blank slate.

“I hope the Baby Boomers do it right.”

Source: